Skip navigation
|
Home
Contact us
Urdu
Confidential Helpline
0845 223 4424
[
Viewing options
]
Search
Hepatitis C Info
Treatment
Living with Hep C
Support
Get Involved
News & Resources
The Trust
News
Media centre
Resources
Trust Updates
Glossary
Community Links
News
2012
2011
2010
December
October
Awareness raising day on the 27th October in Truro
Can Chronic Hepatitis C Patients with Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
Commons debate on blood scandal
Help support the Tainted Blood campaign
Hepatitis C Virus Causes Brain Inflammation Leading to Neuron Injury
Insulin Resistance Linked to Poor Hepatitis C Treatment Response in HIV/HCV Coinfected Patients
Millions of Americans Are Living with Hidden Epidemics
Minister rules out higher pay-out for blood victims
November
Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
Direct-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern
FDA Approves Roche's Second-generation Hepatitis C Viral Load Test
Hepatitis C fears prompt screening
Protease Inhibitor TMC435 Shows Promise Against HCV in Phase 2b Study
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Short-Course Telaprevir Equal to Full-Course in Some Patients With HCV
Specialized Blood Vessels Jumpstart And Sustain Liver Regeneration
Telaprevir Increases Sustained Response Rates and Shortens Treatment Duration for Newly Treated Hepatitis C Patients
The Hepatitis C Trust makes the Clash blog
The Hepatitis C Trust makes Vogue!
Vertex Begins Trial of Telaprevir for Treatment-naive Chronic Hepatitis C Patients
Vertex Completes New Drug Application for Telaprevir for Hepatitis C
The Hepatitis C Trust welcomes review into support for those infected with contaminated blood
Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C
September
August
July
June
May
April
March
February
January
2009
2008
2007
2006
2005
2004
Home
>
News & Resources
>
News
>
2010
>
October
>
November
November
Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
Direct-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern
FDA Approves Roche's Second-generation Hepatitis C Viral Load Test
Hepatitis C fears prompt screening
Protease Inhibitor TMC435 Shows Promise Against HCV in Phase 2b Study
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Short-Course Telaprevir Equal to Full-Course in Some Patients With HCV
Specialized Blood Vessels Jumpstart And Sustain Liver Regeneration
Telaprevir Increases Sustained Response Rates and Shortens Treatment Duration for Newly Treated Hepatitis C Patients
The Hepatitis C Trust makes the Clash blog
The Hepatitis C Trust makes Vogue!
Vertex Begins Trial of Telaprevir for Treatment-naive Chronic Hepatitis C Patients
Vertex Completes New Drug Application for Telaprevir for Hepatitis C
Hepatitis Info
About hep C
Just diagnosed?
Risk factors
Stages of hep C
Considering a test
Symptoms
Cirrhosis
Treatment
Considering
Choosing
Side effects
Preparing for treatment
New drugs
Interferon and ribavirin
Living with
Caring for yourself
Prevention
Mental and emotional
Alternative Medicine
Doctors and Consultants
Support
Support Groups
The importance of support
Helpline
Advocacy
Skipton fund
News & Resources
Resources
Newsletter
Media centre
Get Involved
Volunteering
Fundraising
Campaigning
Become a member
Get tested!
World hepatitis day
Personal stories
About us
Contact us
The team
The work we do
Donate
Resources
Media
About the Trust
[
Sign In
]
[
Sign Up
]